Brain DNA markers link APOE gene to Alzheimer’s risk

The APOE gene has long been known as one of the strongest genetic risk factors for Alzheimer’s disease. But exactly how it raises risk has remained unclear. The study, published in Nature Aging, analysed brain tissue from a large group of deceased donors and identified 107 locations on the DNA where chemical markings (DNA methylation) are associated with Alzheimer’s pathology. Of those 107, 38 were independently replicated.

DNA methylation is a process in which small chemical groups are attached to the DNA. These groups influence whether a gene is active or not, without altering the DNA sequence itself. This falls under epigenetics: the study of how biological and environmental factors determine which genes are switched on or off.

APOE and methylation: a partial explanation

The researchers found that DNA methylation partially mediates the relationship between APOE genotype and an Alzheimer’s diagnosis. In other words, the APOE gene influences how DNA in the brain is marked, and those markings are in turn associated with the presence of Alzheimer’s pathology. That is a link that was previously missing.

This is an observational study on postmortem brain tissue. The findings show an association, but do not establish causation. The researchers cannot rule out that the methylation changes are a consequence of the disease rather than a cause.

What this means for future research

Identifying 38 validated methylation sites opens up new avenues. If specific methylation patterns consistently associate with Alzheimer’s, they could potentially serve as biomarkers, measurable indicators of disease or risk. In the longer term, they may also be targets for treatments that adjust gene activity in the brain.

The scale of the study makes the findings relatively robust. Even so, these are early steps. The path from brain methylation patterns to clinically usable applications is still a long one.

Read the original article